{"DataElement":{"publicId":"6471217","version":"1","preferredName":"Modified Ryan Scheme for Tumor Regression Score 3 Point Scale","preferredDefinition":"The numeric response using a three-point tumor regression grading system used to measure therapeutic response of the primary tumor and predict patient outcomes.","longName":"MRYAN_TRG_SCL","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6471211","version":"1","preferredName":"Modified Ryan Scheme for Tumor Regression Neoplasm Regression Score","preferredDefinition":"A four-point tumor regression grading system that is used to measure therapeutic response of primary tumors and to predict patient outcomes._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._A decrease in the size of a tumor or in the extent of cancer in the body._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"6471208v1.0:6471209v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"6471208","version":"1","preferredName":"Modified Ryan Scheme for Tumor Regression","preferredDefinition":"A four-point tumor regression grading system that is used to measure therapeutic response of primary tumors and to predict patient outcomes.","longName":"C155939","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modified Ryan Scheme for Tumor Regression","conceptCode":"C155939","definition":"A four-point tumor regression grading system that is used to measure therapeutic response of primary tumors and to predict patient outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BAEA5B-9E47-7D02-E053-F662850AE953","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6471209","version":"1","preferredName":"Neoplasm Regression Score","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:A decrease in the size of a tumor or in the extent of cancer in the body.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C3262:C18243:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Regression","conceptCode":"C18243","definition":"Return to a former state; a subsidence of the symptoms of a disease process; in cancer, a decrease in the size of a tumor or in the extent of cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BAEA5B-9E59-7D02-E053-F662850AE953","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BAEA5B-9E6A-7D02-E053-F662850AE953","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2019-03-11","changeDescription":"Curated to support HCMI Stomach_ghd_10.08.18; Released as part of the quarterly draft new clean-up_03.11.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6471212","version":"1","preferredName":"Modified Ryan Scheme for Tumor Regression Score 3 Point Scale","preferredDefinition":"An ordered reference standard related used to measure tumor response to therapeutic procedures using the Modified Ryan Scheme for Tumor Regression Scale.","longName":"MRYAN_TRG_SCORE_SCL","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"3","valueDescription":"Poor or No Response Score 3","ValueMeaning":{"publicId":"6471213","version":"1","preferredName":"Poor or No Response Score 3","longName":"6471213","preferredDefinition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Regression Score 3","conceptCode":"C155944","definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB0BA3-98E0-7BE9-E053-F662850A0581","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BB0BA3-98F9-7BE9-E053-F662850A0581","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"},{"value":"2","valueDescription":"Tumor Regression Score 2","ValueMeaning":{"publicId":"6471214","version":"1","preferredName":"Tumor Regression Score 2","longName":"6471214","preferredDefinition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Regression Score 2","conceptCode":"C155943","definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB0BA3-9905-7BE9-E053-F662850A0581","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BB0BA3-991E-7BE9-E053-F662850A0581","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"},{"value":"1","valueDescription":"Near Complete Response Score 1","ValueMeaning":{"publicId":"6471215","version":"1","preferredName":"Near Complete Response Score 1","longName":"6471215","preferredDefinition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Regression Score 1","conceptCode":"C155942","definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB0BA3-992A-7BE9-E053-F662850A0581","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BB0BA3-9943-7BE9-E053-F662850A0581","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"},{"value":"0","valueDescription":"Complete Response Score 0","ValueMeaning":{"publicId":"6471216","version":"1","preferredName":"Complete Response Score 0","longName":"6471216","preferredDefinition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Regression Score 0","conceptCode":"C155941","definition":"A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB0BA3-994F-7BE9-E053-F662850A0581","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2018-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77BB0BA3-9968-7BE9-E053-F662850A0581","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"ONEDATA","dateModified":"2018-10-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2452834","version":"1","preferredName":"Scale","preferredDefinition":"an ordered reference standard.","longName":"C25664","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scale","conceptCode":"C25664","definition":"An ordered reference standard used to measure incremental changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0D51E8D8-69DD-387C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB0BA3-98C6-7BE9-E053-F662850A0581","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2019-03-11","changeDescription":"Curated to support HCMI Stomach_ghd_10.08.18; Released as part of the quarterly Draft New clean-up_03.11.19_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000437","version":"1","longName":"Stomach","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tumor regression grade","type":"Preferred Question Text","description":"Tumor regression grade","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BB4EDC-44C0-3C19-E053-F662850A0811","latestVersionIndicator":"Yes","beginDate":"2018-10-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-10-08","modifiedBy":"HARTLEYG","dateModified":"2019-03-11","changeDescription":"Curated to support HCMI Stomach Cancer Data Collection_ghd_10.08.18; Released as part of the quarterly Draft New clean-up_03.11.19_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}